Dapiprazole
Not to be confused with Aripiprazole.
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8- tetrahydro-[1,2,4]triazolo[4,5-a]pyridine | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a601043 |
| Pregnancy category |
|
| Routes of administration | Topical (eye drops) |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Negligible when administered topically |
| Identifiers | |
| CAS Number |
72822-12-9 |
| ATC code | S01EX02 (WHO) |
| PubChem | CID 3033538 |
| IUPHAR/BPS | 7155 |
| DrugBank |
DB00298 |
| ChemSpider |
2298190 |
| UNII |
5RNZ8GJO7K |
| KEGG |
D07775 |
| ChEBI |
CHEBI:51066 |
| ChEMBL |
CHEMBL1201216 |
| Chemical data | |
| Formula | C19H27N5 |
| Molar mass | 325.451 g/mol |
| |
| |
| | |
Dapiprazole (Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination.[1]
References
- ↑ Doughty, Michael J.; Lyle, William M. (May 1992). "A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation". Optometry & Vision Science 69 (5).
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
